Advances in neoadjuvant endocrine therapy for hormone receptor-positive/HER-2-negative breast cancer

VernacularTitle:激素受体阳性/HER-2阴性乳腺癌新辅助内分泌治疗研究进展
Author: Bi ZHAO ¹ ; Zheng CHUNHUI ; Wang XUE'ER ; Wang YONGSHENG
Author Information

1. 山东省肿瘤防治研究院(山东省肿瘤医院)乳腺病中心(济南市 250017)
Keywords: breast cancer; hormone receptor-positive/HER-2 negative(HR+/HER2-)subtype; neoadjuvant endocrine therapy(NET); CDK4/6 inhibitors
From: Chinese Journal of Clinical Oncology 2024;51(18):963-967
CountryChina
Language:Chinese
Abstract: Hormone receptor-positive/HER-2-negative(HR+/HER2-)breast cancer exhibits low sensitivity to neoadjuvant chemotherapy(NCT);with minimal benefits observed from NCT.Neoadjuvant endocrine therapy(NET)achieves a clinical response comparable to that of NCT,but with lower toxicity.In addition,CDK4/6 inhibitors have changed the treatment landscape of HR+/HER2-breast cancer,raising new clinical challenges in the selection of the most effective endocrine therapies.In clinical practice,adaptive research designs should be adop-ted based on tumor biology,therapeutic efficacy,and tumor burden.In addition,optimizing treatment strategies and performing precise treatment is important.In this review,we discuss the application value of NET,efficacy evaluating and predicting methods,and potential NET-based combination therapies to provide reference information regarding the treatment of HR+/HER2-breast cancer for clinicians.